Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - avelumab, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: polysorbate 20; mannitol; glacial acetic acid; sodium hydroxide; water for injections - bavencio is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic merkel cell carcinoma (mmcc). this indication is approved based on tumour response rate, duration of response in a single arm study.,bavencio is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (uc) whose disease has not progressed with first-line platinum-based induction chemotherapy.,bavencio in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (rcc).

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - mannitol - solution for infusion - 10 percent - solutions producing osmotic diuresis; mannitol

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mannitol -

Kanada - Kiingereza - Health Canada

fresenius kabi canada ltd - mannitol - solution - 25% - mannitol 25% - osmotic diuretics

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

fresenius kabi ltd - mannitol - infusion - 100mg/1ml

Kenya - Kiingereza - Pharmacy and Poisons Board

beximco pharmaceuticals ltd. 19 dhanmondi r/a road no. 7 dhaka-1205 - mannitol - infusion - mannitol 20% w/v - other irrigating solutions

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 20 per cent

Marekani - Kiingereza - NLM (National Library of Medicine)

baxter healthcare corporation - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 5 g in 100 ml - osmitrol is indicated for: osmitrol is contraindicated in patients with: the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) . no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of mannitol. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. human data published literature reports the presence of mannitol in amniotic f

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium acetate trihydrate - non-small cell lung cancer, pancreatic cancer, biliary tract cancer, uroepithelial cancer, inoperable or recurrent breast cancer, ovarian cancer progressing after chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium acetate trihydrate - non-small cell lung cancer, pancreatic cancer, biliary tract cancer, uroepithelial cancer, inoperable or recurrent breast cancer, ovarian cancer progressing after chemotherapy.